Phase 2 N=30 A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
Fragile X Syndrome · FXS · Fra(X) Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 11; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
Phase 2 N=547 B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
Atopic Dermatitis · Pruritus
Primary: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) — -2.8; -2.8; -2.1 score on a scale — p=0.0148
Phase 2 N=36 A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Acute Myeloid Leukemia · Myelodysplastic Syndromes
Primary: Part A: Maximum Tolerated Dose (MTD) of Bemcentinib (BGB324) — 600; 200 mg
Phase 2 N=48 CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Colorectal Cancer · Colon Cancer · Rectal Cancer
Primary: PHASE I: Recommended Dose for Phase II Study — 1,000 mg/m^2
Phase 2 N=142 Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Primary: Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline — -11.31; -27.59; 2.52; -28.68 percent change…
Phase 2 N=12 A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
Hepatitis B
Primary: Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ) — 25 Percentage of participants
Phase 2 N=127 Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
Cushing's Syndrome
Primary: Number of Participants With Adverse/Serious Adverse Events — 115; 50; 34; 3 Participants
Phase 2 N=117 A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma
Primary: Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by…
Phase 2 N=6 Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Accelerated/Blast-phase Myeloproliferative Neoplasm · Chronic-phase Myelofibrosis · IDH2 Mutation
Primary: Number of MPN Participants With Response — 2 Participants
Phase 2 N=200 Cold Stored Platelet in Hemorrhagic Shock
Trauma · Hemorrhage
Primary: Study Feasibility — 91; 82 Participants
Phase 2 N=1,083 A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
Healthy Participants
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 49.4; 45.8; 54.7; 10.5 Percentage of participants
Phase 2 N=187 Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
NSCLC · HNSCC
Primary: Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed) — 46; 3; 11 Participants
Phase 2 N=100 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Ductal Breast Carcinoma In Situ · Estrogen Receptor Positive
Primary: Change in Ki-67 Labeling Index — -1.0; -4.8 percent positive cells
Phase 2 N=52 Timely Intravenous Magnesium for Asthma in Children
Asthma
Primary: Enrollment — 18; 17; 17 Participants